SCHEMBL5836181

SCHEMBL5836181

COC(=O)c1ccc2c(c1)n(C)c(=O)n2C1CCC1

nearest known ligand 0.53

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ HPD P32754 3/20 0.53
▸ HSD11B1 P28845 2/20 0.49
▸ SMN1; SMN2 Q16637 3/20 0.49
▸ ALDH1A1 P00352 2/20 0.49
▸ ATM Q13315 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ PRKDC P78527 7/20 0.47
▸ PIK3CA P42336 7/20 0.47
▸ RPS6KB1 P23443 1/20 0.47
▸ MTOR P42345 4/20 0.44
▸ DRD2 P14416 1/20 0.44
▸ SLC6A4 P31645 1/20 0.44
▸ KDM4E B2RXH2 1/20 0.43
▸ BRD4 O60885 1/20 0.43
▸ BRPF1 P55201 1/20 0.43
▸ HSD17B10 Q99714 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6208794 0.85 HPD (0.56) HPDHSD11B1SMN1; SMN2ALDH1A1PRKDC
SCHEMBL5836092 0.81 HPD (0.50) HPDHSD11B1SMN1; SMN2ALDH1A1PRKDC
SCHEMBL5836096 0.81 HPD (0.52) HPDHSD11B1SMN1; SMN2ALDH1A1PRKDC
SCHEMBL7539164 0.80 SMN1; SMN2 (0.65) SMN1; SMN2ALDH1A1ATMKDM4EBRD4
SCHEMBL20529086 0.76 PGR (0.53) HSD11B1SMN1; SMN2ALDH1A1ATMNPSR1
SCHEMBL5837066 0.76 ALDH1A1 (0.62) HSD11B1SMN1; SMN2ALDH1A1ATMNPSR1
SCHEMBL5838061 0.75 DRD2 (0.49) HPDHSD11B1PRKDCPIK3CARPS6KB1
SCHEMBL5836683 0.74 KDM4E (0.50) HPDHSD11B1ALDH1A1PRKDCPIK3CA
SCHEMBL28018819 0.74 ALDH1A1 (0.52) HPDSMN1; SMN2ALDH1A1ATMNPSR1
SCHEMBL13635205 0.73 ALDH1A1 (0.51) SMN1; SMN2ALDH1A1ATMNPSR1RPS6KB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7056918-B2 Benzimidazole anti-inflammatory compounds PFIZER, INC. (US) 2006-06-06 — — US disclosed
EP-1370557-B1 BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS PFIZER PROD INC (US) 2005-11-16 — — EP disclosed
EP-1370557-A1 BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS Pfizer Products Inc. (US) 2003-12-17 — — EP disclosed
US-20030092749-A1 Novel benzimidazole anti-inflammatory compounds PFIZER INC. 2003-05-15 — — US disclosed
WO-2002072576-A1 BENZIMIDAZOLE ANTI-INFLAMMATORY COMPOUNDS PFIZER PRODUCTS INC. (US) 2002-09-19 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030092749-A1 Novel benzimidazole anti-inflammatory compounds MAPK1, JAK1, CNKSR1 HPD 4598/4885HSD11B1 3213/4885SMN1; SMN2 1612/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback